—First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage— BRIDGEWATER, N ...
-First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage- BRIDGEWATER, N ...
Novartis's disastrous week — three clinical failures that vaporized more than $40 billion in market value — has done more than damage one company.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. AstraZeneca on Friday detailed the ...
BARCELONA—AstraZeneca AZN-0.31%decrease; down pointing triangle said its new drug for chronic obstructive pulmonary disease showed benefits across a broad patient population in late-stage clinical ...
Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced that ...
Imagine trying to live a normal life when you can’t stop coughing or you’re too breathless to walk. For many people living with bronchiectasis, that’s the reality they face every day. Recurring ...
NICE is unable to make a recommendation on brensocatib (Brinsupri) for treating non-cystic fibrosis bronchiectasis in people 12 years and over. This is because the company did not provide an evidence ...
OBERON and TITANIA were double-blind, placebo-controlled Phase III trials enrolling just over 2,300 patients with a history of two or more moderate or one or more severe COPD exacerbations in the ...
Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results